A hybrid radioactive and fluorescence approach is more than the sum of its parts; outcome of a phase II randomized sentinel node trial in prostate cancer patients-Reference-Cited by-同舟云学术

A hybrid radioactive and fluorescence approach is more than the sum of its parts; outcome of a phase II randomized sentinel node trial in prostate cancer patients

Published:2023-04-10 Issue:9 Volume:50 Page:2861-2871
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Wit Esther M. K.,KleinJan Gijs H.,Berrens Anne-Claire,van Vliet Roos,van Leeuwen Pim J.,Buckle Tessa,Donswijk Maarten L.,Bekers Elise M.,van Leeuwen Fijs W. B.,van der Poel Henk G.

Funder

H2020 European Research Council

Stichting voor de Technische Wetenschappen

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00259-023-06191-7.pdf

Reference51 articles.

1. Peek MC, Charalampoudis P, Anninga B, Baker R, Douek M. Blue dye for identification of sentinel nodes in breast cancer and malignant melanoma: a systematic review and meta-analysis. Future Oncol. 2017;13(5):455–67.

2. Valiveru RC, Agarwal G, Agrawal V, Gambhir S, Mayilvaganan S, Chand G, et al. Low-cost fluorescein as an alternative to radio-colloid for sentinel lymph node biopsy-a prospective validation study in early breast cancer. World J Surg. 2020;44(10):3417–22.